Gleevec Sales Data
| Rank 24 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Gleevec U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 24 ( 1) |
$498,149 | 7.22% | 81 | 3.85% |
| Q3 2013 | 25 ( 1) |
$464,588 | -1.68% | 78 | -11.36% |
| Q2 2013 | 24 (2) |
$472,509 | 7.85% | 88 | 7.32% |
| Q1 2013 | 26 | $438,105 | 0.41% | 82 | -5.75% |
| Q4 2012 | 26 (1) |
$436,298 | -4.10% | 87 | -5.43% |
| Q3 2012 | 25 (9) |
$454,935 | 10.57% | 92 | 9.52% |
| Q2 2012 | 34 (4) |
$411,455 | 5.21% | 84 | 6.33% |
| Q1 2012 | 38 (2) |
$391,072 | 0.13% | 79 | -8.14% |
| Q4 2011 | 36 (1) |
$390,547 | 4.38% | 86 | 3.61% |
| Q3 2011 | 35 (2) |
$374,171 | 5.88% | 83 | -2.35% |
| Q2 2011 | 37 (3) |
$353,382 | 1.64% | 85 | 1.19% |
| Q1 2011 | 40 | $347,690 | n/a | 84 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
